17-AAG聚氰基丙烯酸正丁酯纳米粒的制备及抗肿瘤活性研究

doi:10.3969/j.issn.1006-7795.2015.02.005

首都医科大学学报 ›› 2015, Vol. 36 ›› Issue (2): 178-184.doi: 10.3969/j.issn.1006-7795.2015.02.005

17-AAG聚氰基丙烯酸正丁酯纳米粒的制备及抗肿瘤活性研究

闫岩¹, 王玉记², 吴建辉², 崔纯莹¹

1. 首都医科大学化学生物学与药学院药剂学系, 北京 100069;
2. 首都医科大学化学生物学与药学院药物化学系, 北京 100069

收稿日期:2014-12-08 出版日期:2015-04-21 发布日期:2015-04-16
通讯作者: 崔纯莹 E-mail:ccy@ccmu.edu.cn
基金资助:
"十二五"重大新药创制科技重大专项(2011ZX09302-007-01)。

Studies on anticancer activity of 17-AAG poly-butylcyanoacrylate nanoparticles

Yan Yan¹, Wang Yuji², Wu Jianhui², Cui Chunying¹

1. Department of Pharmaceutics, School of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China;
2. Department of Medicinal Chemistry, School of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China

Received:2014-12-08 Online:2015-04-21 Published:2015-04-16
Supported by:
This study was supported by Significant New Drugs Creation "Five-year" Plan Special Science and Technology Major(2011ZX09302-007-01).

摘要/Abstract

摘要： 目的制备一种新型17-丙烯氨基-17-去甲氧基格尔德霉素聚氰基丙烯酸正丁酯纳米粒(17-allylamino-17-demethoxygeldanamycin poly-butylcyanoacrylate nanoparticles,17-AAG-PBCA-NPs)。方法采用界面聚合法制备17-AAG-PBCA-NPs;采用正交实验筛选最优处方;采用纳米粒度仪、透射电镜、扫描电镜对17-AAG-PBCA-NPs进行表征和鉴定;采用动态透析法测定体外释放药物情况;采用四甲基偶氮唑盐[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,MTT]考察17-AAG-PBCA-NPs对5种人肿瘤细胞株增生的抑制作用;以荷S180小鼠为模型,考察17-AAG-PBCA-NPs的抗肿瘤活性。结果界面聚合法制备的17-AAG-PBCA-NPs包封率大于90%,粒径为(180.5±12.0)nm,Zata电位为(-28.38±0.81)mV,表面形态规则均匀;17-AAG-PBCA-NPs呈时间依赖性地抑制肿瘤细胞株增生,动物实验表明,17-AAG-PBCA-NPs抗肿瘤活性比17-AAG强,毒性比17-AAG低。结论采用界面聚合法可制备得到17-AAG-PBCA-NPs,制备方法简单、重现性好、包封率高,并显示了较好的抗肿瘤活性。

关键词: 17-丙烯氨基-17-去甲氧基格尔德霉素聚氰基丙烯酸正丁酯纳米粒(17-AAG), 聚氰基丙烯酸正丁酯, 抗肿瘤

Abstract: Objective To prepare 17-allylamino-17-demethoxygeldana-mycin poly-butylcyanoacrylate nanoparticles(17-AAG-PBCA-NPs) and study the anticancer activity of 17-AAG poly-butylcyanoacrylate nanoparticles. Methods 17-AAG was encapsulated in PBCA-NPs by interfacial polymerization method. Using single factor analysis combined with orthogonal design to compare the effect factors on 17-AAG-PBCA-NPs, optimizing the preparation method of 17-AAG-PBCA-NPs. Nanoparticle size analyzer, TEM and SEM were used to identify and analyze the characteristics of 17-AAG-PBCA-NPs. The dynamic dialysis method was used to determine the in vitro release of 17-AAG-PBCA-NPs. Results Optimal dosage of drug mass ratio was 1∶10. The conditions of the reaction system were: pH 2, 1 200 r/min, F-68, 3% Dextran70. The time of polymerization was 3 hours. The optimal encapsulation efficiency was more than 90%. The morphology of 17-AAG-PBCA-NPs was spherical shape with (180.5±12.0) nm in diameter and the Zeta potential ranged from -20 to -30 mV. The release of 17-AAG-PBCA-NPs in vitro was determined by dynamic dialysis method and it has been shown that the release of drug from the PBCA-NPs exhibited a rapid burst release followed by a sustained release. 17-AAG-PBCA-NPs showed good stability in plasma. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay of the 17-AAG-PBCA-NPs and 17-AAG using HepG2, A375, HeLa, MCF-7 and SHSY5Y cell line showed that the 17-AAG-PBCA-NPs and 17-AAG inhibited the growth of HepG2, A375, HeLa, MCF-7 and SHSY5Y cells, showing a time-dependent manner, respectively. Furthermore, in vivo anti-tumor activity of 17-AAG-PBCA-NPs was evaluated in sarcoma bearing mice following intraperitoneal injection. Compared with 17-AAG, 17-AAG-PBCA-NPs achieved superior sustained-release effect, and extended the dosing interval further, increased tolerated dose, reduced the side effect of the drug, and improved the compliance to medication, safety and medication. Conclusion 17-AAG-PBCA-NPs were prepared by using interfacial polymerization method. Further optimization of the preparation method is both beneficial to the characteristic and sustained release effect of 17-AAG-PBCA-NPs.

Key words: 17-allylamino-17-demethoxygeldanamycin(17-AAG), poly-butylcyanoacrylate, antitumor

中图分类号:

R965.1

闫岩, 王玉记, 吴建辉, 崔纯莹. 17-AAG聚氰基丙烯酸正丁酯纳米粒的制备及抗肿瘤活性研究[J]. 首都医科大学学报, 2015, 36(2): 178-184.

Yan Yan, Wang Yuji, Wu Jianhui, Cui Chunying. Studies on anticancer activity of 17-AAG poly-butylcyanoacrylate nanoparticles[J]. Journal of Capital Medical University, 2015, 36(2): 178-184.

参考文献

[1] Whitesell L, Lindquist S L. HSP90 and the chaperoning of cancer[J]. Na Rev Cancer, 2005,5(10):761-772.
[2] Sauvageot C M, Weatherbee J L, Kesari S, et al. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells[J]. Neuro Oncol, 2009,11(2):109-121.
[3] Önyüksel H, Mohanty P S, Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin:a novel targeted nanomedicine for breast cancer[J]. Int J Pharm, 2009,365(1):157-161.
[4] Yordanov G, Evangelatov A, Skrobanska R. Epirubicin loaded to pre-polymerized poly(butyl-cyanoacrylate) nanoparticles:Preparation and in vitro evaluation in human lung adenocarcinoma cells[J]. Colloids Surf B Biointerfaces, 2013,107:115-123.
[5] Reddy L H, Murthy R S R. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butyl-cyanoacrylate) nanoparticles synthesized by two different techniques[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2004,148(2):161-166.
[6] Hu Y, Jiang X, Ding Y, et al. Preparation and drug release behaviors of nimodipine-loaded poly(caprolactone)-poly(ethylene oxide)-polylactide amphiphilic copolymer nanoparticles[J]. Biomaterials, 2003,24(13):2395-2404.
[7] Zhang Y, Zhang Y, Chen J, et al. Polybutylcyanoacrylate nanoparticles as novel vectors in cancer gene therapy[J]. Nanomedicine, 2007,3(2):144-153.
[8] Mulik R, Mahadik K, Paradkar A. Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles:physicochemical characterization and stability study[J]. Eur J Pharm Sci, 2009,37(3):395-404.
[9] Joshi S A, Chavhan S S, Sawant K K. Rivastigmine-loaded PLGA and PBCA nanoparticles:Preparation, optimization, characterization, in vitro and pharmacodynamic studies[J]. Eur J Pharm Biopharm, 2010,76(2):189-199.
[10] Nippe S, General S. Combination of injectable ethinyl estradiol and drospirenone drug-delivery systems and characterization of their in vitro release[J]. Eur J Pharm Sci, 2012,47(4):790-800.
[11] Huang C Y, Lee Y D. Core-shell type of nanoparticles composed of poly copolymers for drug delivery application:Synthesis, characterization and in vitro degradation[J]. Int J Pharm, 2006,325(1):132-139.
[12] Dunne M, Corrigan O I, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles[J]. Biomaterials, 2000,21(16):1659-1668.
[13] 肖丽君,赵恩宏,赵爽,等.17-AAG对MCF-7细胞增殖的抑制作用及对STAT3和VEGF表达的影响[J].中国医科大学学报,2013,42(1):65-68.

17-AAG聚氰基丙烯酸正丁酯纳米粒的制备及抗肿瘤活性研究

Studies on anticancer activity of 17-AAG poly-butylcyanoacrylate nanoparticles

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

本文评价

[1]	李飞阳, 崔纯莹, 王玉记, 吴建辉. 阿霉素脂质体的制备及抗肿瘤活性研究[J]. 首都医科大学学报, 2015, 36(2): 157-160.
[2]	邢璐, 崔纯莹, 王玉记, 房晨婕, 吴建辉. 巯嘌呤/维拉帕米-介孔氧化硅释药系统的构建及逆转耐药活性研究[J]. 首都医科大学学报, 2015, 36(2): 161-165.
[3]	魏丽艳, 崔纯莹, 吴建辉, 王玉记. 以海豹油为基质的多西紫杉醇脂肪乳的制备及其抗肿瘤活性研究[J]. 首都医科大学学报, 2015, 36(2): 192-198.
[4]	李雪梅, 王玉记, 吴建辉, 崔纯莹. RGD脂肪醇与17-AAG脂质体的制备及抗肿瘤活性研究[J]. 首都医科大学学报, 2015, 36(2): 172-177.
[5]	史凡, 崔纯莹, 吴建辉, 王玉记. 多西紫杉醇-海豹油纳米结构脂质载体的抗肿瘤活性评价[J]. 首都医科大学学报, 2015, 36(2): 185-191.
[6]	崔永, 柳明亮, 吴炳群, 段新春, 龚民. 紫杉醇-顺铂联合药物控释系统对肺腺癌细胞系A549细胞生长的抑制作用[J]. 首都医科大学学报, 2014, 35(6): 694-697.
[7]	张晶, 刘伟, 陈云雨, 司书毅. 以保罗样激酶1为靶点的抗肿瘤药物的筛选及活性评价[J]. 首都医科大学学报, 2014, 35(3): 337-343.
[8]	徐艳霞;赵明;王玉记;吴建辉;李莉;张建伟;康贵峰;彭师奇. 药物设计中的伪肽先导结构的发现[J]. 首都医科大学学报, 2010, 31(5): 614-622.
[9]	李金凤;张震宇;王淑珍;刘晋玮. 卵巢癌细胞和脐血树突状细胞融合瘤苗的体外培养与免疫原性的研究[J]. 首都医科大学学报, 2007, 28(5): 604-608.